NCT01654861终止1 期
Evaluation of the Safety and Efficacy of Standard Dose Gemcitabine Combined With High Dose Intravenous Vitamin C (HDIVC) Treatment for Patients With Metastatic Adenocarcinoma of the Pancreas.
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 入组人数
- 3
- 试验地点
- 1
- 主要终点
- Adverse Events as a Measure of Safety and Tolerability
研究概览
简要总结
- The combination of gemcitabine and HDIVC is safe and may favorably change the clinical course for an individual patient.
- The combination of gemcitabine and HDIVC is synergistic in anti-tumor effect as seen in preclinical models, where HDIVC creates a pro-oxidative effect that adds to the anti-tumor effect of gemcitabine.
- The combination of gemcitabine and HDIVC may improve Progression Free Survival (PFS).
- The dosage schema of 1.2 g /kg bolus infusion followed by lower dose of 0.3 g / kg infusion may create sustained elevation in Vitamin C plasma levels for increased cytotoxic effect.
- The addition of HDIVC & oral supplementation of Vitamin C to standard treatment with gemcitabine may improve quality of life for patients with comparison to prior to treatment start of this protocol.
- CA 19-9 and inflammatory markers may show trends for patients in this trial.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patient ≥ 18 years of age
- •Biopsy proven adenocarcinoma of the pancreas
- •Evidence of metastatic disease
- •Received at least 1 prior chemotherapy treatment regimen with disease progression
- •May have had any prior chemotherapy regimen including any gemcitabine based regimen or FOLFIRINOX
- •May have participated in a prior study protocol
- •May have had prior treatment with HDIVC
- •Anticipated survival of at least 3 months
- •Eastern Cooperative Oncology Group (ECOG) performance status = 0,1, or 2
- •The patient must have screening laboratory: ANC ≥ 1,500/mm3, Hemoglobin > 8g/dL, Platelets ≥ 100,000/mm3, Total Bilirubin < 1.5mg/dL, Creatinine ≤ 1.5mg/dL, Transaminases < 2.5 x upper limit of normal, Urine Uric Acid < 1.000 mg/d, Urine pH < 6, Urine microscopic negative for oxalates (if positive, reflex urinary oxalates < 60mg/d), PT INR ≤ 1.5, unless patient is on full dose warfarin
- •Glucose-6-phosphate dehydrogenase deficiency (G6PD) normal status via blood test The fluorescent spot test is the simplest, most reliable, and most sensitive of the G6PD screening tests
- •Willingness to undergo central line placement and able to manage care of the entry site safely
- •Willingness to adhere to supplemental oral dose regimen of ascorbic acid 500mg taken twice daily
- •All other nutritional supplements would be discontinued for the duration of the trial except for pancreatic enzymes and probiotics
- •Patients must be able to take food orally or have a peg tube for feeding
- •Able to give consent for protocol participation
排除标准
- •Glucose-6-phosphate dehydrogenase deficiency (G6PD)
- •Renal insufficiency : serum creatinine of > 1.5 mg /dl or evidence of oxalosis by urinalysis prior to enrollment and prior to each HDIVC infusion
- •Documentation or report of history of kidney stones or urinary oxalosis.
- •Co-morbid condition that would affect survival: congestive heart failure, unstable angina, myocardial infarction within 6 weeks of study, uncontrolled blood sugars of > 300 mg / dl, patients with known chronic active hepatitis or cirrhosis
- •Currently active second malignancy
- •Chronic hemodialysis
- •Iron overload/ Hemochromatosis: Ferritin > 500 ng / ml
- •Wilson's disease
- •Pregnant or lactating female (pre- menopausal females will undergo pregnancy test prior to administration of protocol drugs throughout treatment cycles during this study)
- •Aspirin use exceeding 81 mg per day
- •Acetaminophen use exceeding 2 g per day
- •Known brain metastasis
- •Active tobacco smokers
- •Treatment with the combination of HDIVC and gemcitabine previously
研究组 & 干预措施
HDIVC
Experimental
Gemcitabine (Gemzar), Intravenous and oral Ascorbic Acid (Vitamin C).
干预措施: Gemcitabine, Intravenous and oral Ascorbic Acid (Vitamin C) (Drug)
结局指标
主要结局
Adverse Events as a Measure of Safety and Tolerability
时间窗: Weekly for up to 6 months.
Adverse events, whether volunteered by the study subject, discovered by the investigators during questioning, or detected by physical examination, laboratory tests, or other means will be collected and recorded at each visit. Events will be recorded from the time the consent is signed until 4 weeks after the study protocol is discontinued. Subjects experiencing Grade 4 neutropenia, Grade ≥3 thrombocytopenia, or Grade 2 peripheral neuropathy who do not recover will have treatment protocol discontinued.
次要结局
- Anti-Tumor Response(Every 2 months for up to 6 months.)
研究者
研究点 (1)
Loading locations...
相似试验
终止
1 期
GEMHDM2014 : Gem-HDM HDT and ASCT for Relapsed/ Refractory LymphomaHodgkin's Lymphoma - Relapsed/RefractoryNon-Hodgkin's Lymphoma - AggressiveFollicular LymphomaNCT02295722AHS Cancer Control Alberta100
终止
1 期
A Study Evaluating Gemcitabine Plus Bosutinib for Patients With Resected Pancreatic CancerPancreatic CancerNCT01025570University of California, San Francisco3
已完成
2 期
Neoadjuvant Chemo (Gemcitabine and Cisplatin) With Radical Cystectomy or Radiotherapy in Patients With Bladder CancerBladder CancerNCT00490880Eli Lilly and Company2
已完成
1 期
Gemcitabine and Capecitabine in Patients With Advanced Pancreatic CancerPancreatic CancerNCT00316420Swedish Medical Center20
Unknown
1 期
Safety and Efficacy Evaluation of iAPA-DC/CTL Combined Gemcitabine Therapy on Advanced Pancreatic CancerCarcinoma, Pancreatic DuctalNCT02529579Changhai Hospital187